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A b s t r a c t  Factor XIIIa (FXIIIa), a coagulation transglu- 
taminase, is a cytoplasmic marker for dermal dendritic 
cells reported to be bone marrow-derived, phagocytic 
and antigen-presenting. In non-inflamed skin, these cells 
populate the papillary dermis in a perivascular distribu- 
tion. They are increased in dermatoproliferative disor- 
ders and have been implicated as dermal stimulants for 
psoriatic hyperkeratosis. Since developing skin provides 
an example of dermal influence on the epidermis, we 
evaluated the presence of FXIIIa + cells in human fetal 
skin to determine whether their location would suggest a 
role in morphogenetic events in the skin. Embryonic and 
fetal skin of progressive estimated gestational ages 
(EGA) was examined using immunocytochemistry with 
a polyclonal antibody to FXIIIa. At 6 weeks EGA, glob- 
ular FXIIIa + cells were present in the hypodermis. By 
7-8 weeks, a compact sub-epidermal network of fusi- 
form FXIIIa + cells was also evident. By 11-12 weeks, 
the sub-epidermal cellular network was no longer 
FXIIIa +, but discrete FXIIIa + dendritic cells were present 
in the reticular dermis. With advancing gestational age, 
FXIIIa + dendritic cells populated the papillary dermis in 
a perivascular distribution. This adult-like distribution 
persisted through 22 weeks EGA, the oldest specimen 
examined. Because FXIIIa + cells were evident in embry- 
onic skin before the onset of bone marrow hematopoietic 
function, the skin was double-labeled with the FXIIIa 
antibody and with monoclonal antibodies to CD45 
(marker for bone marrow-derived cells), CD68 (marker 
for macrophages) and HLA-DR (class II major histo- 
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compatibility antigen). Most of the FXIIIa + dendritic 
cells did not colocalize CD45, but were CD68+; some 
cells did react with the HLA-DR antibody. Notably, the 
FXIIIa + cells of the sub-epidermal network in the 7 
weeks EGA specimens did not react with the other anti- 
bodies. We conclude that FXIIIa + cells are first present 
in embryonic hypodermis and sub-epidermal dermis and 
later they are distributed in the papillary dermis in a peri- 
vascular pattern. In embryonic skin FXIIIa + cells are not 
exclusively dendritic. Our data support the idea that cells 
that express FXIIIa do not constitute a unique bone mar- 
row-derived cell type, but that multiple cell types pro- 
duce FXIIIa. 
K e y  w o r d s  Fetal skin 9 Dermal dendrocyte 9 FXIIIa 9 
CD45 9 CD68 
Introduction 
The dermal dendrocyte is a phagocyte characterized by 
the expression of the blood transglutaminase clotting 
protein factor XIIIa (FXIIIa) (Headington 1986; Cerio et 
al. 1989a, b; Cerio et al. 1990; Estrada and Pi6rard 
1990). The cell resembles a fibroblast morphologically, 
but expresses markers characteristic of bone marrow-de- 
rived, antigen-presenting inflammatory cells (Cerio et al. 
1989b; Sontheimer 1989; Sontheimer et al. 1989; Cerio 
et al. 1990; Estrada and Pi6rard 1990). In normal adult 
skin, the dermal dendrocyte is perivascular within the 
papillary and upper reticular dermis (Cerio et al. 1989b; 
Nickoloff and Griffiths 1989a, b; Sontheimer 1989; Son- 
theimer et al. 1989). Its presence in inflammatory der- 
matoses (e.g. psoriasis, eczema), Kaposi's sarcoma, der- 
matofibromas and acute burn wounds, but not in mature 
scars, keloids or fibroproliferative diseases (Nemes and 
Thomazy 1988; Cerio et al. 1988; Nickoloff and Griffiths 
1989a, b; Nemeth and Penneys 1989; Cerio et al. 1989b; 
Toida et al. 1989; Penneys 1990; Cerio and Jones 1990a, 
b; Gray etal. 1990; Gray etal. 1991; Penneys etal. 
1991; Regezi et al. 1993; Gibran et al. 1995a), suggests 
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that the dermal dendrocyte plays a role in the cellular 
phase of inflammatory processes. 
It is distinct from the dendritic epidermal Langerhans 
cell by location, by negative reactivity with antibodies to 
CDla (Headington 1986; Cerio et al. 1989b; Sontheimer 
et al. 1989) and by the absence of Birbeck granules (Mos- 
chella and Cropley 1990) and ATPase activity (Heading- 
ton 1986). The dermal dendrocyte is considered to be 
bone marrow-derived, based on data that FXIIIa+ dermal 
cells stain with antibodies to CD45, a surface marker for 
bone marrow-derived cells, CD1 lb, a leukocyte specific 
antigen, CD68, a macrophage marker (Headington 1986; 
Sontheimer 1989; Cerio et al. 1989b, 1990; Sontheimer et 
al. 1989; Estrada and Ptrard 1990; Weber-Matthiesen and 
Sterry 1990). It is considered to be a phagocyte, based on 
the presence of vacuoles containing hemosiderin and mel- 
anin (Cerio et al. 1990) and is thought to be antigen-pre- 
senting as determined by positive labeling with antibodies 
to CD1 lb, CD14, CD36 and the class II major histocom- 
patibility complex HLA-DR (Drijkoningen et al. 1987; 
Sontheimer 1989; Cerio et al. 1989b; Weber-Matthiesen 
and Sterry 1990). The immunophenotype of the dermal 
dendrocyte overlaps that of other antigen-presenting in- 
flammatory cells in the skin and it may serve many of the 
same functions, but it is specifically identifiable because 
of its FXIIIa expression, dendritic appearance and dermal 
location. The literature is sufficiently controversial to 
make the identification of this cell equivocal. It may, in 
fact, be a unique phenotype of a common cell that can ex- 
press CD1 under some conditions, contain Birbeck gran- 
ules during periods of membrane endocytosis and express 
fibroblast markers at other times. Even the dendritic con- 
formation may be dependent on the cell's attendant role 
and location. 
Identification of the dermal dendrocyte in inflamma- 
tory conditions provides one perspective of the cell's po- 
tential role in the skin. Other aspects of morphogenesis, 
such as development, provide an opportunity to ask how 
the cell might relate to morphogenetic events that in- 
volve epidermal-mesenchymal interactions and whether 
it can arise from sources other than bone marrow such as 
the yolk sac or an uncommitted mesenchymal cell? 
Embryonic and fetal human skin was evaluated for the 
immunolocalization of FXIIIa § dendritic cells. Further 
characterization of the FXIIIa § cells was pursued by ex- 
amining the skin for other cell markers; because dermal 
dendrocytes are reputed to be bone marrow-derived, the 
tissue was also stained with antibodies to CD45, the mark- 
er for bone marrow-derived cells, and CD68, the marker 
for macrophages/monocytes. An antibody to the major 
histocompatibility antigen HLA-DR was used to examine 
antigen presenting capacities of the FXIIIa + cells. 
Materials and methods 
Human Skin 
Thirty-six specimens of human fetal skin ranging from 6 to 22 
weeks estimated gestational age (EGA) were examined for this 
study. Fetal age was determined by foot length and crown-rump 
length. The tissue was obtained through the Central Laboratory for 
Human Embryology in accordance with the regulations of the 
University of Washington Human Subjects Review Board and with 
DHEW policies. No identifying data for any of the patients were 
available to the investigators. The tissue was immersed in Car- 
noy's fixative overnight, dehydrated, paraffin-embedded and cut in 
6 gm sections. 
Immunocytochemistry 
Initial studies with tissue frozen in OCT demonstrated that unfixed 
tissue stained with greater intensity but with no difference in dis- 
tribution of positive cells. Also, trypsin treatment enhanced the 
FXIIIa staining, but did not change the distribution of positive 
cells. Therefore, Carnoy's fixed tissue without protease treatment 
was used for all the experiments. The immunocytochemistry was 
performed using a previously described immunoperoxidase tech- 
nique (Gibran et al. 1994b). Deparaffinized sections were incubat- 
ed with 3% H202 and incubated in 1% bovine serum albumin that 
was also used as a diluent for the polyclonal antibody to FXIIIa 
(1:1000; CalBiochem, Calif., USA). Biotinylated anti-rabbit IgG 
(1:300; Vector Laboratories, Calif., USA) was used followed by 
Streptavidin AH-biotin amplification (Zymed Laboratories, Calif., 
USA). All rinses were performed in 0.01 M TRIS saline pH 7.4. 
The chromagen was 0.1% 3',3'-diaminobenzidine (Sigma Chemi- 
cal Co, Mo., USA), and hematoxylin was used as a nuclear coun- 
terstain. Control specimens without primary antibody were includ- 
ed in each immunochemical run. Slides were dehydrated and cov- 
erslipped using Histomount (National Diagnostics, N.J., USA). 
The slides were photographed using a Zeiss Standard microscope 
with planapochromatic lenses. 
For double-immunolabeling experiments, a previously de- 
scribed immunofluorescent method was used (Gibran etal. 
1995a). The sections were deparaffinized, incubated with the 1% 
BSA and incubated with monoclonal antibodies to CD-68 (1:400; 
Dakopatts Calif., USA), a marker for monocytes/macrophages; 
CD-45 (1:25; Dakopatts), a marker for bone marrow-derived cells; 
or HLA-DR (1:70, Dakopatts), the class II major histocompatibili- 
ty antigen. Biotinylated anti-mouse IgG antibody (1:200; Vector 
Laboratories) was followed by incubation with rhodamine 600- 
avidin D (1:1500; Vector Laboratories). After TRIS saline rinses, 
the slides were again incubated with 1% BSA followed by the 
polyclonal antibody to FXIIIa (1:100) and finally fluorescein la- 
beled anti-rabbit IgG antibody (1:40; Vector Laboratories). Con- 
trol slides without primary antibody were included in these runs. 
Slides were coverslipped with Fluoromount-G (Southern Biotech- 
nology Associated) and photographed within 48 h using a Zeiss 
Standard microscope and a Zeiss filter (excitation wavelengths 
450-490). 
Results 
At 6 weeks EGA, globular FXIIIa + cells were present in 
the hypodermis, but FXIIIa + dendritic cells were not 
present in the dermis or epidermis. The FXIIIa + cells in 
the hypodermis were large and round, typical of a tissue 
macrophage (Fig. la). By 7-8 weeks EGA, a compact 
sub-epidermal network of fusiform FXIIIa + cells resem- 
bling fibroblasts was present in addition to the globular 
cells in the hypodermis (Fig. lb). By 11-12 weeks, glob- 
ular FXIIIa + cells still populated the hypodermis and 
dendritic FXIIIa + cells were present in the deep dermis, 
but the sub-epidermal network of compact mesenchymal 
cells was no longer FXIIIa + (Fig. lc, d). The dendritic 
FXIIIa + cells were concentrated around capillaries in the 
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Fig. 1 Light micrographs from: a 6-week, b 7-week, c 11-week, d 
14-week, e 21-week, f 22 week human embryos and fetuses im- 
munolabeled with an antibody to factor XIII subunit a. Note the 
presence of FXIIIa § globular (open arrows) and dendritic (curved 
arrows) within the hypodermis as early as 6 weeks EGA (a). The 
band of sub-epidermal cells is evident in the early dermis, but is 
absent from older skin (a, b arrowheads). The perivascular cellu- 
lar distribution is illustrated in e, e and the absence of an associa- 
tion with epidermal appendages is shown in d. The presence of 
FXIIIa + cells in the epidermis is evident in f. Bar 25 gin 
pap i l l a ry  dermis  in a d is t r ibut ion s imi lar  to that  in adul t  
skin (Fig.  lc ) .  The  pap i l l a ry  dis t r ibut ion o f  dendri t ic  
F X I I I a  § cel ls  pers i s ted  through our  o ldes t  (22 weeks)  
E G A  spec imen  (Fig.  l e ,  f). Wi th  increas ing  ges ta t ional  
age,  there  was an apparent  p rogress ion  o f  F X I I I a  § den- 
dri t ic cel ls  wi th in  the re t icular  dermis  towards  the papi l -  
lary dermis  and ep ide rmis  wi th  a decrease  in the number  
o f  g lobular  F X I I I a  § cel ls  in the hypodermis .  F X I I I a  § 
cel ls  d id  not  appear  to have specif ic  re la t ionships  wi th  
deve lop ing  ep ide rma l  appendages .  
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Fig. 2 Skin sections from a 7-week EGA embryo double-labeled 
with immunofluorescence using antibodies to: a, c, e factor XIIIa, 
b CD45, d CD68 or f HLA-DR. Broken line delineates the dermal- 
epidermal junction. Open arrows depict examples of cells that lo- 
calize only FXIIIa. Solid arrows illustrate examples of cells that 
localize both cell markers. Bar 25 gm 
Further characterization of these cells with double-la- 
beling demonstrated variable co-localization of FXIIIa 
with CD45, CD68 and HLA-DR. The sub-epidermal net- 
work seen at 7-8 weeks did not immunostain with anti- 
bodies to CD68, CD45 or HLA-DR (Fig. 2a-f). Many 
FXIIIa + globular cells in the hypodermis were immuno- 
reactive with the antibody to CD45, whereas many den- 
dritic dermal FXIIIa + cells did not localize CD45. This 
pattern persisted through all of the gestational ages ex- 
amined (Figs. 2a, b, 3a, b). Except for the FXIIIa + sub- 
epidermal cellular network, FXIIIa + cells routinely co- 
localized CD68 (Figs. 2c, d, 3c, d). HLA-DR localized to 
some but not all of the FXIIIa + cells in the dermis (Figs. 
2e, f, 3e, f). Expression of HLA-DR did not correlate 
with the morphological shape of the cells. 
Discussion 
The potential sources and role of  Factor XIIIa + cells have 
not been definitively determined. Data about the dermal 
dendrocyte's presence in different dermatopathologic 
states and conclusions about its presumptive role are often 
conflicting (Nemes and Thomazy 1988; Cerio et al. 1988; 
Nemeth and Penneys 1989; Nickoloff and Griffiths 1989a, 
b; Cerio et al. 1989b; Toida et al. 1989; Penneys 1990; Ce- 
rio and Jones 1990a, b; Gray et al. 1990, 1991; Penneys et 
al. 1991; Regezi et al. 1993; Gibran et al. 1994a). Distinc- 
tion of the dermal dendrocyte from fibroblasts, macro- 
phages, Langerhans cells and other dendritic cells of the 
immune system has been based on immunocytochemical 
localization of cell markers. There is no direct evidence 
that the dermal dendrocyte is a unique cell type. Rather, 
FXIIIa + cells may represent a phenotype of dermal mesen- 
chymal cells that are sufficiently plastic to express differ- 
ent cell markers at specific stages of differentiation and/or 
the cell cycle and also to alter morphology based on the 
extracellular matrix and neighboring cells. 
Our earliest embryonic tissue has large round FXIIIa § 
cells, resembling other tissue macrophages, in the hypo- 
dermis. However, FXIIIa + cells never appear globular in 
the papillary dermis in any embryonic or fetal skin speci- 
mens, suggesting that the hallmark spindle-shape mor- 
phology of the dermal dendrocyte may depend on loca- 
tion, extracellular matrix architecture or specific cellular 
interactions. Alternatively, FXIIIa may be expressed by 
several cell types, including fibroblasts and macrophages 
and each cell type may be able to express Factor XIIIa 
under specific, yet undefined, conditions. 
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Fig. 3 Skin sections from a 22-week EGA fetus double-labeled 
with immunofluorescence using antibodies to: a, c, e factor XIIIa 
and either b CD45, d CD68 or f HLA-DR. Open arrows depict ex- 
amples of cells that localize only FXIIIa. Solid arrows illustrate 
examples of cells that localize both cell markers. Bar 25 gm 
Nickoloff has suggested that dermal dendrocytes in- 
crease their expression of TNF~ in psoriatic lesions and 
has proposed that this induces an autocrine hyperprolif- 
erative response by the overlying keratinocytes (Nickol- 
off et al. 1991). Trimble and colleagues, in their investi- 
gation of  FXIIIa + cells in developing human tissues, re- 
ported a sub-epidermal "cambium" of FXIIIa + cells in 
the skin (Trimble et al. 1992), but the authors did not re- 
port variation in this cellular localization with gestational 
age. Our data suggest that the sub-epidermal concentra- 
tion of FXIIIa + cells is transient and is present at the 
stage when the epithelium stratifies from a two-cell-lay- 
ered structure to a three-layered epidermis and thus may 
support the hypothesis that FXIIIa + dendritic cells influ- 
ence epithelial celt proliferation. We did not observe a 
specific relationship between FXIIIa + cells and develop- 
ing epidermal appendages at any gestational age that 
would suggest a relationship between FXIIIa + cells and 
epithelial morphogenesis. However, signaling between 
dermal FXIIIa + cells and epidermal cells during early 
gestation may contribute to the eventual development of 
epidermis-derived structures. 
The first evidence of the perivascular localization of 
the FXIIIa + dendritic cells, a distribution that has been 
well described in adult skin, occurs at 10-11 weeks 
EGA, the period of transition between embryonic and fe- 
tal development, and coincident with the establishment 
of the subpapillary plexus (Johnson and Holbrook 1989). 
Our data suggest that the presence of FXIIIa + dendritic 
cells in the papillary dermis is not dependent on dermal 
vascularity alone, since the earlier embryonic specimens 
have dermal capillary networks but no papillary dermal 
FXIIIa + cells. Nevertheless, the vessel distribution in 
older fetal skin is more continuous than at younger ge- 
stational ages (Johnson and Holbrook 1989) and may al- 
low greater cellular migration to the extracellular space. 
Wagner has proposed that endothelial and blood cells 
differentiate from a common mesenchymal stem cell that 
is derived from yolk sac blood islands (Wagner 1980). 
Therefore, our identification of FXIIIa + dermal dendritic 
cells at an embryonic stage, when the dermal vasculature 
is also developing, might relate to the common origins of 
endothelial cells and bone marrow-derived cells. This 
close relationship between the hematopoietic System and 
endothelial cells may also be illustrated by evidence that 
endothelial cells stimulated in vitro upregulate FXIIIa 
expression (Karasek 1991). 
Although FXIIIa + cells have been reported to be bone 
marrow-derived (Headington 1986; Sontheimer 1989; 
Cerio et al. 1989b; Sontheimer et al. 1989; Estrada and 
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Pitrard 1990; Weber-Matthiesen and Sterry 1990; Cerio 
et al. 1990), our data indicate that FXIIIa + cells exist in 
the skin as early as 6-7 weeks EGA, prior to hematopoi- 
etic function by the bone marrow (Keleman and Calvo 
1982). Moreover, FXIIIa + dendritic cells in the fetal and 
embryonic dermis only sporadically localize CD45, the 
marker for bone marrow-derived cells. This suggests that 
non-bone-marrow-derived mesenchymal cells may tran- 
siently express FXIIIa or that uncommitted cells may 
differentiate to become FXIIIa + dendritic cells. Co-local- 
ization of CD68, a surface marker for macrophages, on 
FXIIIa + cells supports the hypothesis that the dermal 
dendrocyte belongs to an inflammatory cell lineage; 
therefore, the cells could derive from the yolk sac and 
settle in the dermiS as tissue macrophages that undergo 
phenotypic change, including expression of FXIIIa, in 
response to appropriate stimuli. Eighty-five percent of 
non-stimulated FXIIIa + cells have been reported to ex- 
press the class II major histocompatibility antigen HLA- 
DR (Cerio et al. 1989b). Our observations of HLA-DR 
expression by embryonic and fetal FXIIIa + cells corre- 
late with published data and do not appear to vary with 
gestational age. Variable HLA-DR expression may indi- 
cate that not all FXIIIa + cells are constitutively stimulat- 
ed to present antigens. Alternatively FXIIIa + cells may 
represent multiple cell types With common expression of 
a ubiquitous enzyme; some of the FXIIIa + cells may be 
antigen-presenting cells and others may be non-inflam- 
matory cells. Our data are supported by other recent re- 
ports of phenotypic and functional subsets of FXIIIa + 
dermal cells. Expression of either the CDla or CD14 an- 
tigen and the ability of the CDla + cells to induce T cell 
proliferation has been reported as a distinguished feature 
of different subsets of FXIIIa + dermal cells (Nestle et al. 
1993). Therefore, the variable expression of HLA-DR in 
our tissues is expected and may reflect different states of 
FXIIIa + cells or may represent different cell types that 
are all capable of FXIIIa expression. 
To conclude, we have demonstated that more than one 
population of FXIIIa + cells may be present in embryonic 
and fetal skin. Our data suggest that the enzyme is pres- 
ent in a population of tissue macrophage-like cells in the 
hypodermis, a transient fusiform network of fibroblast- 
like cells in the sub-epidermal dermis and a perivascular 
dendritic population in the papillary dermis. Variable ex- 
pression of inflammatory cell surface markers on the 
FXIIIa + cells in embryonic and fetal specimens suggest 
that multiple phenotypes of FXIIIa + cells exist or that 
multiple clell types have the potential to express FXIIIa. 
These results support the possibility that the bone mar- 
row is not the only source for FXIIIa + cells. We suggest 
that multiple cell types may express FXIIIa, similar to 
the expression of other transglutaminases by terminally 
differentiated cells (Jetten and Shirley 1986; Piacentini 
et al. 1991), rather than FXIIIa being a specific marker 
for a unique cell type. 
Acknowledgements The authors are grateful for the excellent 
photographic assistance of Mr. Robert Underwood and to Mrs. 
Marcia Usui for proofreading the manuscript. This work was sup- 
ported in part by NIH grants T32 GM07037 and HD 17664 and by 
a research grant from Dermik Laboratories. 
References 
Cerio R, Jones EW (1990a) Factor XIIIa in fibrovascular tumors 
(letter). J Cutan Pathol 17:251 
Cerio R, Jones EW (1990b) Factor XIIIa positivity in fibrous pap- 
ule (letter). J Am Acad Dermatol 22:138-139 
Cerio R, Spaull J, Jones EW (1988) Identification of factor XIIIa 
in cutaneous tissue (letter). Histopathology 13:362-364 
Cerio R, Griffiths C, Cooper K, Nickoloff B J, Headington JT 
(1989a) The immunophenotype of FXIIIa dendritic cells in 
normal and inflamed skin (abstract). J Invest Dermatol 92:437 
Cerio R, Griffiths CE, Cooper KD, Nickoloff B J, Headington JT 
(1989b) Characterization of factor XIIIa-positive dermal den- 
dritic cells in normal and inflamed skin. Br J Dermatol 121: 
421-431 
Cerio R, Spaull J, Oliver GF, Jones WE (1990) A study of factor 
XIIIa and MAC 387 immunolabeling in normal and pathologi- 
cal skin. Am J Dermatopathol 12:221-233 
Drijkoningen M, De Wolf-Peeters C, Van Der Steen K, Moerman 
E Desmet V (1987) Epidermal Langerhans cells and dermal 
dendritic cells in human fetal and neonatal skin: an immuno- 
histochemical study. Pediatr Dermatol 4:11-17 
Estrada JA, Pitrard GE (1990) Factor XIIIa positive dendrocytes 
and the dermal microvascular unit. Dermatologica 180:51-53 
Gibran NS, Heimbach DM, Holbrook KA (1995a) Immunolocal- 
ization of FXIIIa+ dendritic cells in human burn wounds. J 
Surg Res (in press) 
Gibran N, Isik F, Heimbach D, Gordon D (1994b) Basic fibroblast 
growth factor in the early human burn wound. J Surg Res 56: 
226-234 
Gray MH, Smoller BR, McNutt NS, Hsu A (1990) Immunohisto- 
chemical demonstration of factor XIIIa expression in neurofi- 
bromas. A practical means of differentiating these tumors 
from neurotized melanocytic nevi and schwannomas. Arch 
Dermatol 126:472-476 
Gray MH, Trimble CL, Zirn J, McNutt NS, Smoller BR, Varghese 
M (1991) Relationship of factor XIIIa-positive dermal dendr- 
ocytes to Kaposi's sarcoma. Arch Pathol Lab Med 115:791-796 
Headington JT (1986) The dermal dendrocyte. In: Callen JR Dahl 
MV, Golitz LE, Rasmussen JE, Stegmen SJ (eds) Adv Derma- 
tol Yearbook Medical Publishers, Chicago, pp 159-171 
Jetten AM, Shirley JE (1986) Characterization of transglutaminase 
activity in rabbit tracheal epithelial cells. Regulation: by retino- 
ids. J Biol Chem 261:15097-15101 
Johnson CL, Holbrook KA (1989) The development of dermal 
vasculature. J Invest Dermatol 93:10S-t7S 
Karasek MA, Lipton B, Mansbridge J (1991) Induction of macro- 
phage markers in activated skin microvascular endothelial 
cells (abstract). J Invest Dermatol 96:564 
Keleman E, Calvo W (1982) Prenatal hematopoiesis in human 
bone marrow and its developmental antecedents. In: Trubowitz 
S, Davis S (eds) The human bone marrow: anatomy, physiolo- 
gy, and pathophysiology. CRC Press, Boca Raton, pp 3-41 
Moschella SL, Cropley TG (1990) Mononuclear phagocytic and 
dendritic cell systems. J Am Acad Dermatol 22:1091-1097 
Nemes Z, Thomazy V (1988) Factor XIIIa and the classic histio- 
cytic markers in malignant fibrous histiocytoma: a compara- 
tive immunohistochemical study. Hum Pathol 19:822-829 
Nemeth AJ, Penneys NS (1989) Factor XIIIa is expressed by fi- 
broblasts in fibrovascular tumors. J Cutan PAthol 16:266-271 
Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ 
(1993) Characterization of dermal dendritic cells obtained 
from normal human skin reveals phenotypic and functionally 
distinctive subsets. J Immunol 151:1-12 
Nickoloff B J, Griffiths CE (1989a) Factor XIIIa-expressing der- 
mal dendrocytes in AIDS-associated cutaneous Kaposi's sar- 
comas. Science 243:1736-1737 
Nickoloff B J, Griffiths CE (1989b) The spindle-shaped cells in cu- 
taneous Kaposi's sarcoma. Histologic simualtors include fac- 
tor XIIIa dermal dendrocytes. Am J Pathol 135:793-800 
Nickoloff B J, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mit- 
ra RS, Elder JT, Kunkel SL, Dixit VM (1991) Cellular local- 
ization of interleukin-8 and its inducer, tumor necrosis factor- 
alpha in psoriasis. Am J Pathol 138:129-140 
Penneys NS (1990) Factor XIII expression in the skin: observa- 
tions and a hypothesis. J Am Acad Dermatol 22:484-488 
Penneys NS, Smith KJ, Nemeth AJ (1991) Factor XIIIa in the 
hamartomas of tuberous sclerosis. J Dermatol Sci 2:50-54 
Piacentini M, Autuori F, Dini L, Farrace MG, Ghibelli L, Piredda 
L, Fesus L (1991) Tissue transglutaminase is specifically ex- 
pressed in neonatal rat liver cells undergoing apoptosis upon 
epidermal growth factor-stimulation. Cell Tissue Res 263: 
227-235 
Regezi JA, MacPhail LA, Daniels TE, DeSouza YG, Greenspan 
JS, Greenspan D (1993) Human immunodeficiency virus-asso- 
ciated oral Kaposi's sarcoma. A heterogeneous cell population 
dominated by spindle-shaped endothelial cells. Am J Pathol 
143:240-249 
41 
Sontheimer RD (1989) Perivascular dendritic macrophages as im- 
munobiological constituents of the human dermal microvascu- 
lar unit. J Invest Dermatol 93:96S-101S 
Sontheimer RD, Matsubara T, Seelig LL (1989) A macrophage 
phenotype for a constitutive, class II antigen-expressing hu- 
man dermal perivascular dendritic cell. J Invest Dermatol 93: 
154-159 
Toida M, Watanabe F, Tsai CS, Okutomi T, Tatematsu N, Oka N 
(1989) Factor XIIIa-containing cells and fibrosis in oral and 
maxillofacial lesions: an immunohistochemical study. Oral 
Surg Oral Med Oral Pathol 68:293-299 
Trimble CL, Gray MH, McNutt NS (1992) The distribution of fac- 
tor XIIIa-positive cells in the human fetus and placenta. Vir- 
chows Arch A Pathol Anat Histopathol 420:513-518 
Wagner RC (1980) Endothelial cell embryology and growth. Adv 
Microcirc 9:45-75 
Weber-Matthiesen K, Sterry W (1990) Organization of the mono- 
cyte/macrophage system of normal human skin. J Invest Der- 
mato195:83-89 
